click enter text
updat model ge deal dental separ
updat view maintain outperform rate share
rais price target prior estim
includ dental ex non-control interest ge
revis ep estimate con revis ep estimate
con number go lower
dental remov higher addit ge
plu adjust non-op/corpor item
net impact non-op/corpor item incl corpor
expens go lower match run rate ex-tim item ex dental net
ge-rel spend lower interest incom reflect capit deploy
ge deal trade ebitda estim premium
lst coverag pt reflect
estim near current market fcfi group given recent cfo
commentari pharma academ survey dhr indic
above-guid result rais underli organ growth
incl cytiva/g
dental extract detail previous estim drag
remov dental versu latest model exclud non-
control interest ipo share swap share
lower share count posit prior estim
result net drag dental compar prior
model neg impact share count reduct
larger impact estim growth dental ebit
trade fundament data
upsid target
gross benefit inclus ge full year exclud
impact financ share count alreadi model
base deal close end prior model includ
share issuanc european debt rais remov
benefit interest incom cash balanc relat european debt
start close ge deal prior model model
fulli reflect move piec ge deal includ ebit benefit
financ cost lower forecast interest rate us debt add
modestli estim accret ge deal estim net
accret ge deal modestli ahead rang given manag
adjust one quarter delay close
report limit sole use client wolf research pleas refer disclosur section locat end
report analyst certif import disclosur disclosur
page
exhibit revenu mix continu move toward life
exhibit ge come fastest grow busi segment
note dental move discontinu op
note total organ revenu growth ex dental
page
revenu mix segment dentalenviro/applieddiagnosticsg lslife sciencesorgan revenu growth bpsge bp bp bpstotal org ebit margin expansionorg ebit mgnfx impact a/othernomin price-to-earnings premium tool median median median
exhibit organ sale growth segment
note lower ep reflect shift cap deploy benefit
page
annual guidancea nvstorgan growth ex itemsgaap guidancea nvstorgan growth ex itemsgaap revenu profit incom mm dilut share outstand growth pro-forma pro-forma
exhibit organ growth trend product line
page
page
yieldfcf compound-annual-growth-rate ebitda compound-annual-growth-rate ev-ebitda vs estimate ebitda compound-annual-growth-rate tool ntm price-to-earnings ratio median price-to-earnings premium compound-annual-growth-rate
note figur million unless state per-shar term
page
note figur million unless state per-shar term
page
 sale detail mn adjust sell day revenu wr organ bp bpsm estimate bp bp bp bp bp bp bp bp bp bp bp bp bpsother estimate bp bp bp bp bp bp bp bp bp bp bp bp bp bp wr organ bp bpsm bp bp bp bp bp bp bp bp bp bp bp bp bp bp bp bp bp bpsother bp bp bp bp bp bp bp bp bp bp bp bp bp bp bp bp bp bp cepheid impactsal sale op ex sale sales-driven ebit impact wr organ bp bpsm bp bp bp bp bp bp bp bp bp bp bp bp bpsother bp bp bp bp bp bp bp bp bp bp bp bp bp bp bp bp bp bp bp bpscytiva ge wr organ bp bp bp bp bp bpsm estimate bp bp bp bp bp bp bp bp bp bpsother estimate bp bp bp bp bp bp bp bp bp bpsebit ebitlif ebit life margin
